Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zai Lab's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zai Lab's regulatory disclosures and financial reporting.
ZLAB affiliate filed a Form 144 to sell up to 5,199 American Depositary Shares following restricted stock vesting. The filing lists the ADS as vested on 04/01/2026 with the broker-dealer Fidelity Brokerage Services LLC. The filing also shows a prior sale of 1,703 ADS on 03/13/2026.
Zai Lab Ltd director Richard Gaynor bought 1,731 American Depositary Shares in an open‑market transaction at $18.91 per ADS. After this purchase, he directly holds 56,630 ADS. The trade was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 16, 2025.
Zai Lab Ltd reported that officer Joshua L. Smiley received new equity awards and completed routine vesting and tax-related sales. On March 4, 2026, he was granted 103,950 stock options with an exercise price of $19.27 per ADS and 33,783 restricted share units (RSUs), each RSU representing one American Depositary Share (ADS). These options and RSUs vest in equal annual installments over four years beginning on March 4, 2027, subject to continuous service. On March 12, 2026, 6,388 RSUs vested and were settled in ADSs, and on March 13, 2026, 1,966 ADSs were sold at $18.628 per ADS automatically to cover taxes. After these transactions, Smiley directly holds 91,026 ADSs, along with remaining RSU and option awards scheduled to vest over time.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported multiple equity compensation moves. On March 4, 2026, he received stock options for 83,160 American Depositary Shares (ADSs) at an exercise price of $19.27 per ADS, expiring on March 4, 2036, plus 27,027 Restricted Share Units (RSUs). Both awards vest in equal annual installments over four years beginning in 2027, subject to continuous service.
On March 12, 2026, 4,258 RSUs were exercised into the same number of ADSs, and on March 13, 2026 he sold 1,281 ADSs at $18.628 per ADS. Footnotes state these ADSs were sold automatically to cover taxes upon vesting of RSUs. After these transactions, he directly holds 6,494 ADSs.
Zai Lab Ltd Chief Financial Officer Yajing Chen received new equity compensation and reported related share activity. On March 4, 2026, Chen was granted 83,160 stock options with an exercise price of $19.27 per American Depositary Share (ADS), expiring on March 4, 2036, and 27,027 Restricted Share Units (RSUs). These options and RSUs vest in equal annual installments over four years beginning on March 4, 2027, subject to continuous service.
On March 12, 2026, 4,258 RSUs vested and converted into the same number of ADSs, and on March 13, 2026, 1,703 ADSs were sold at $18.628 per ADS. According to the footnotes, these ADSs were sold automatically to cover taxes due upon RSU vesting, rather than as a discretionary open-market sale. After these transactions, Chen held 19,999 ADSs directly.
Zai Lab Ltd officer Rafael Amado reported compensation-related equity activity and a small share sale. He received stock options for 103,950 American Depositary Shares (ADSs) at an exercise price of $19.27 per ADS, expiring in 2036, and 33,783 Restricted Share Units (RSUs) linked to ADSs.
On March 12, 2026, 5,323 RSUs were exercised into the same number of ADSs, increasing his direct ADS holdings. On March 13, 2026, he sold 2,957 ADSs at $18.628 per ADS, with a footnote stating these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, he directly held 44,757 ADSs and 15,971 RSUs. Each ADS represents ten ordinary shares.
Zai Lab Ltd reported new equity awards to Chairperson and CEO Ying Du. On March 11, 2026, Du received stock options for 353,430 American Depositary Shares (ADSs) with an exercise price of 19.34 per ADS, expiring on March 11, 2036.
The filing also shows a grant of 32,419 Restricted Share Units (RSUs), each representing one ADS. Both the options and RSUs vest in equal annual installments over four years beginning on March 11, 2027, subject to continuous service. Each ADS represents ten ordinary shares of Zai Lab.
ZLAB files a notice of proposed sale of 1,281 American Depositary Shares with an aggregate reported value of $23,862.72 dated 03/13/2026. The filing identifies the sale method as related to Restricted Stock Vesting and lists recent dispositions by Frazor T. Edmondson.
The record shows two dispositions in the prior three months: 8,651 ADS sold on 12/16/2025 for $148,278.14, and 15,569 ADS sold on 03/05/2026 for $296,745.14.
ZLAB reporting person Rafael Amado reported dispositions of American Depositary Shares. The filing lists sales of 10,787 ADS on 12/31/2025 for $188,033.59 and 10,000 ADS on 03/03/2026 for $173,800.00. The filing also shows 2,957 ADS vested as restricted stock on 03/12/2026 for compensation.